Zheng ZM, Baker CC (2006) Papillomavirus genome structure, expression, and post-
transcriptional regulation. Front Biosci: J Virtual Libr 11:2286–2302
Doorbar J, Egawa N, Griffin H, Kranjec C, Murakami I (2015) Human papillomavirus molecu-
lar biology and disease association. Rev Med Virol 25(Suppl 1):2–23
Zheng ZM (2010) Viral oncogenes, noncoding RNAs, and RNA splicing in human tumor
viruses. Int J Biol Sci 6:730–755
Wiest T, Schwarz E, Enders C, Flechtenmacher C, Bosch FX (2002) Involvement of intact
HPV16 E6/E7 gene expression in head and neck cancers with unaltered p53 status and per-
turbed pRb cell cycle control. Oncogene 21:1510–1517
Evander M, Frazer IH, Payne E, Qi YM, Hengst K, McMillan NA (1997) Identification of the
alpha6 integrin as a candidate receptor for papillomaviruses. J Virol 71:2449–2456
Joyce JG, Tung JS, Przysiecki CT, Cook JC, Lehman ED, Sands JA, Jansen KU, Keller PM
(1999) The L1 major capsid protein of human papillomavirus type 11 recombinant virus-like
particles interacts with heparin and cell-surface glycosaminoglycans on human keratinocytes.
J Biol Chem 274:5810–5822
Juckett G, Hartman-Adams H (2010) Human papillomavirus: clinical manifestations and pre-
vention. Am Fam Physician 82:1209–1213
Ikenberg H (2014) Laboratory diagnosis of human papillomavirus infection. Curr Probl
Dermatol 45:166–174
Wiwanitkit V (2013) Cervista HPV HR test kit in cervical cancer screening. J Low Genit Tract
Dis 17:99
Johnson LR, Starkey CR, Palmer J, Taylor J, Stout S, Holt S, Hendren R, Bock B, Waibel E,
Tyree G, Miller GC (2008) A comparison of two methods to determine the presence of high-
risk HPV cervical infections. Am J Clin Pathol 130:401–408
Rebolj M, Preisler S, Ejegod DM, Bonde J, Rygaard C, Lynge E (2013) Prevalence of Human
Papillomavirus infection in unselected SurePath samples using the APTIMA HPV mRNA
assay. J Mol Diagn: JMD 15:670–677
Wright TC, Stoler MH, Behrens CM, Sharma A, Zhang G, Wright TL (2015) Primary cervical
cancer screening with human papillomavirus: end of study results from the ATHENA study
using HPV as the first-line screening test. Gynecol Oncol 136:189–197
Forouzanfar MH, Foreman KJ, Delossantos AM, Lozano R, Lopez AD, Murray CJ, Naghavi
M (2011) Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic
analysis. Lancet (London, England) 378:1461–1484
Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto
J, Meijer CJ, Munoz N (1999) Human papillomavirus is a necessary cause of invasive cervical
cancer worldwide. J Pathol 189:12–19
Schiffman M, Kjaer SK (2003) Chapter 2: natural history of anogenital human papillomavirus
infection and neoplasia. J Natl Cancer Inst Monogr 31:14–19
de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, Tous S, Felix
A, Bravo LE, Shin HR, Vallejos CS, de Ruiz PA, Lima MA, Guimera N, Clavero O, Alejo M,
Llombart-Bosch A, Cheng-Yang C, Tatti SA, Kasamatsu E, Iljazovic E, Odida M, Prado R,
Seoud M, Grce M, Usubutun A, Jain A, Suarez GA, Lombardi LE, Banjo A, Menendez C,
Domingo EJ, Velasco J, Nessa A, Chichareon SC, Qiao YL, Lerma E, Garland SM, Sasagawa
T, Ferrera A, Hammouda D, Mariani L, Pelayo A, Steiner I, Oliva E, Meijer CJ, Al-Jassar WF,
Cruz E, Wright TC, Puras A, Llave CL, Tzardi M, Agorastos T, Garcia-Barriola V, Clavel C,
Ordi J, Andujar M, Castellsague X, Sanchez GI, Nowakowski AM, Bornstein J, Munoz N,
Bosch FX (2010) Human papillomavirus genotype attribution in invasive cervical cancer: a
retrospective cross-sectional worldwide study. Lancet Oncol 11:1048–1056
Giuliano AR, Harris R, Sedjo RL, Baldwin S, Roe D, Papenfuss MR, Abrahamsen M, Inserra
P, Olvera S, Hatch K (2002) Incidence, prevalence, and clearance of type-specific human pap-
illomavirus infections: The Young Women’s Health Study. J Infect Dis 186:462–469
Castle PE, Dockter J, Giachetti C, Garcia FA, McCormick MK, Mitchell AL, Holladay EB,
Kolk DP (2007) A cross-sectional study of a prototype carcinogenic human papillomavirus E6/
